Clinical trials
Renal Cell Carcinoma clinical trials
Below are recruiting renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 526 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06903312RecruitingPhase 4
Removing the main kidney tumor during immunotherapy for advanced kidney cancer
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
RomaAges 18 years+ - NCT06916624Recruiting
Study of a new PET tracer for kidney cancer imaging
This trial is testing a new imaging agent called 18F-NY104 to see if it can help doctors see kidney cancer tumors on a PET/CT scan. If you have known or suspected kidney cancer that has spread or come back, this study may help find out if the tracer works for you.
Qingdao, ShandongAges 18–75 - NCT06934057RecruitingPhase 4
Cabozantinib and Nivolumab for older adults with kidney cancer
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
AngersAges 70 years+ - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06947668Recruiting
Biomarker study for people who can't take cisplatin chemo
This study looks at immune system markers in patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. The goal is to understand how well a different chemotherapy drug (docetaxel) combined with radiation works in these patients.
Erlangen, BavariaAges 18 years+ - NCT06995664Recruiting
Higher radiation dose for kidney cancer that has spread
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
LondonAges 18 years+ - NCT07018037Recruiting
TTV levels during first immunotherapy for kidney cancer
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
Rome, RomeAges 18 years+ - NCT07023432RecruitingPhase 2
Belzutifan vs. watchful waiting for slow-growing kidney cancer
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
Houston, TexasAges 18 years+ - NCT07037004RecruitingPhase 2
Testing a gut health supplement with immunotherapy after kidney cancer surgery
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
Duarte, CaliforniaAges 18 years+ - NCT07062549RecruitingPhase 1
New imaging agent for metastatic clear cell kidney cancer
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Baltimore, MarylandAges 18 years+ - NCT07063212RecruitingPhase 2
Sacituzumab govitecan plus cetuximab for head and neck cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT07067905RecruitingEarly Phase 1
PET scan test for glioblastoma and kidney cancer
This trial tests a new PET scan tracer called [68Ga]Ga-XT771 to see if it can better detect glioblastoma (a type of brain tumor) and clear cell renal cell carcinoma (a type of kidney cancer). If you have one of these cancers, this scan might help your doctor see the tumor more clearly.
BeijingAges 18 years+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07117227Recruiting
Study to test a kidney cancer prediction model
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Beijing, Beijing MunicipalityAges 18–80 - NCT07118813Recruiting
AI predicts kidney cancer surgery outcomes
This trial uses artificial intelligence to read CT scans and predict how well kidney cancer patients will do after surgery. It aims to help doctors plan better treatment for you.
Wuhan, HubeiAges 18 years+ - NCT07128680RecruitingPhase 1
Immunotherapy with or without a gut bacteria pill for kidney cancer
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Duarte, CaliforniaAges 18 years+ - NCT07166445Recruiting
Using AI to read kidney cancer CT scans for better staging
This study uses a computer program (deep learning) to look at your kidney CT scan and tell if your cancer is more advanced (stage T3) or earlier (stage T1-T2). The goal is to help doctors plan the best treatment for you.
BeijingAges 18–85 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07175480RecruitingPhase 2
Stopping treatment for kidney cancer based on PET/CT results
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Nanjing, JiangsuAges 18 years+ - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07217028RecruitingPhase 1
Safety study of a new PET tracer for head and neck cancer
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
Nashville, TennesseeAges 18 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell carcinoma?
- Yes. Clin2 currently lists 526 recruiting renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.